Tokyo Tape
Sign in
← Falco Holdings

Half-year report · Q2

4671.TEDINET S100UP43
Period2024-04-01 → 2024-09-30
Filed2024-11-12
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 47
MetricValuePeriodScopeSource row
Revenue¥21.4bn2024-04-01 → 2024-09-30Cons.Net sales
Revenue¥43.0bn2023-04-01 → 2024-03-31Cons.Net sales (5-year summary)
Revenue¥21.3bn2023-04-01 → 2023-09-30Cons.Net sales
Operating income¥974m2024-04-01 → 2024-09-30Cons.Operating income
Operating income¥851m2023-04-01 → 2023-09-30Cons.Operating income
Ordinary income¥1.0bn2024-04-01 → 2024-09-30Cons.Ordinary income
Ordinary income¥2.3bn2023-04-01 → 2024-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥931m2023-04-01 → 2023-09-30Cons.Ordinary income
Profit before tax¥1.2bn2024-04-01 → 2024-09-30Cons.Income before income taxes
Profit before tax¥1.1bn2023-04-01 → 2023-09-30Cons.Income before income taxes
Net income (owners)¥794m2024-04-01 → 2024-09-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥1.7bn2023-04-01 → 2024-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥629m2023-04-01 → 2023-09-30Cons.Profit loss attributable to owners of parent
Net income¥794m2024-04-01 → 2024-09-30Cons.Profit loss
Net income¥629m2023-04-01 → 2023-09-30Cons.Profit loss
Total assets¥36.2bnat 2024-09-30Cons.Assets
Total assets¥36.4bnat 2024-03-31Cons.Assets
Total assets¥36.7bnat 2023-09-30Cons.Total assets (5-year summary)
Total liabilities¥10.2bnat 2024-09-30Cons.Liabilities
Total liabilities¥10.4bnat 2024-03-31Cons.Liabilities
Net assets / equity¥25.9bnat 2024-09-30Cons.Net assets
Net assets / equity¥26.0bnat 2024-03-31Cons.Net assets
Net assets / equity¥26.0bnat 2023-09-30Cons.Net assets (5-year summary)
Cash and deposits¥10.6bnat 2024-09-30Cons.Cash and deposits
Cash and deposits¥10.1bnat 2024-03-31Cons.Cash and deposits
Cash & equivalents¥10.6bnat 2024-09-30Cons.Cash and cash equivalents
Cash & equivalents¥10.1bnat 2024-03-31Cons.Cash and cash equivalents
Cash & equivalents¥9.2bnat 2023-09-30Cons.Cash and cash equivalents
Cash & equivalents¥12.6bnat 2023-03-31dCons.Cash and cash equivalents
Operating cash flow¥1.4bn2024-04-01 → 2024-09-30Cons.Net cash provided by used in operating activities
Operating cash flow¥3.4bn2023-04-01 → 2024-03-31Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥1.7bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in operating activities
Investing cash flow−¥73m2024-04-01 → 2024-09-30Cons.Net cash provided by used in investment activities
Investing cash flow−¥1.4bn2023-04-01 → 2024-03-31Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥1.9bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in investment activities
Financing cash flow−¥860m2024-04-01 → 2024-09-30Cons.Net cash provided by used in financing activities
Financing cash flow−¥4.5bn2023-04-01 → 2024-03-31Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow−¥3.2bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in financing activities
EPS (basic)¥74.462024-04-01 → 2024-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥151.722023-04-01 → 2024-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥56.292023-04-01 → 2023-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (diluted)¥74.252024-04-01 → 2024-09-30Cons.Diluted earnings per share (5-year summary)
EPS (diluted)¥150.92023-04-01 → 2024-03-31Cons.Diluted earnings per share (5-year summary)
EPS (diluted)¥56.142023-04-01 → 2023-09-30Cons.Diluted earnings per share (5-year summary)
Equity ratio71.4%at 2024-09-30Cons.Equity to asset ratio (5-year summary)
Equity ratio71.2%at 2024-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio70.6%at 2023-09-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 36
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2024-04-01 → 2024-09-30¥0
Reconciling Itemsreconcilingrevenue intersegment2024-04-01 → 2024-09-30¥0
Reconciling Itemsreconcilingsegment profit2024-04-01 → 2024-09-30−¥176m
jpcrp040300-q2r_E04982-000Clinical Testing Businessreportable segmentrevenue2024-04-01 → 2024-09-30¥13.1bn
jpcrp040300-q2r_E04982-000Clinical Testing Businessreportable segmentrevenue external2024-04-01 → 2024-09-30¥13.1bn
jpcrp040300-q2r_E04982-000Clinical Testing Businessreportable segmentrevenue intersegment2024-04-01 → 2024-09-30¥0
jpcrp040300-q2r_E04982-000Clinical Testing Businessreportable segmentsegment profit2024-04-01 → 2024-09-30¥726m
jpcrp040300-q2r_E04982-000Dispensing Pharmacy Businessreportable segmentrevenue2024-04-01 → 2024-09-30¥7.7bn
jpcrp040300-q2r_E04982-000Dispensing Pharmacy Businessreportable segmentrevenue external2024-04-01 → 2024-09-30¥7.7bn
jpcrp040300-q2r_E04982-000Dispensing Pharmacy Businessreportable segmentrevenue intersegment2024-04-01 → 2024-09-30¥0
jpcrp040300-q2r_E04982-000Dispensing Pharmacy Businessreportable segmentsegment profit2024-04-01 → 2024-09-30¥347m
jpcrp040300-q2r_E04982-000ICT Businessreportable segmentrevenue2024-04-01 → 2024-09-30¥538m
jpcrp040300-q2r_E04982-000ICT Businessreportable segmentrevenue external2024-04-01 → 2024-09-30¥538m
jpcrp040300-q2r_E04982-000ICT Businessreportable segmentsegment profit2024-04-01 → 2024-09-30¥76m
—segment totalrevenue2024-04-01 → 2024-09-30¥21.4bn
—segment totalrevenue external2024-04-01 → 2024-09-30¥21.4bn
—segment totalrevenue intersegment2024-04-01 → 2024-09-30¥0
—segment totalsegment profit2024-04-01 → 2024-09-30¥1.1bn
Reconciling Itemsreconcilingrevenue2023-04-01 → 2023-09-30¥0
Reconciling Itemsreconcilingrevenue intersegment2023-04-01 → 2023-09-30¥0
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2023-09-30−¥270m
jpcrp040300-q2r_E04982-000Clinical Testing Businessreportable segmentrevenue2023-04-01 → 2023-09-30¥13.0bn
jpcrp040300-q2r_E04982-000Clinical Testing Businessreportable segmentrevenue external2023-04-01 → 2023-09-30¥13.0bn
jpcrp040300-q2r_E04982-000Clinical Testing Businessreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥0
jpcrp040300-q2r_E04982-000Clinical Testing Businessreportable segmentsegment profit2023-04-01 → 2023-09-30¥689m
jpcrp040300-q2r_E04982-000Dispensing Pharmacy Businessreportable segmentrevenue2023-04-01 → 2023-09-30¥7.9bn
jpcrp040300-q2r_E04982-000Dispensing Pharmacy Businessreportable segmentrevenue external2023-04-01 → 2023-09-30¥7.9bn
jpcrp040300-q2r_E04982-000Dispensing Pharmacy Businessreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥0
jpcrp040300-q2r_E04982-000Dispensing Pharmacy Businessreportable segmentsegment profit2023-04-01 → 2023-09-30¥385m
jpcrp040300-q2r_E04982-000ICT Businessreportable segmentrevenue2023-04-01 → 2023-09-30¥449m
jpcrp040300-q2r_E04982-000ICT Businessreportable segmentrevenue external2023-04-01 → 2023-09-30¥449m
jpcrp040300-q2r_E04982-000ICT Businessreportable segmentsegment profit2023-04-01 → 2023-09-30¥46m
—segment totalrevenue2023-04-01 → 2023-09-30¥21.3bn
—segment totalrevenue external2023-04-01 → 2023-09-30¥21.3bn
—segment totalrevenue intersegment2023-04-01 → 2023-09-30¥0
—segment totalsegment profit2023-04-01 → 2023-09-30¥1.1bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 522
ItemContextValueUnit
Income taxes refund ope cfPrior1YTDDuration362000000JPY
Income taxes refund ope cfCurrentYTDDuration－JPY
Net cash provided by used in operating activitiesPrior1YTDDuration1660000000JPY
Net cash provided by used in operating activitiesCurrentYTDDuration1420000000JPY
Purchase of property plant and equipment inv cfPrior1YTDDuration-688000000JPY
Purchase of property plant and equipment inv cfCurrentYTDDuration-172000000JPY
Proceeds from sales of property plant and equipment inv cfPrior1YTDDuration70000000JPY
Proceeds from sales of property plant and equipment inv cfCurrentYTDDuration16000000JPY
Purchase of intangible assets inv cfPrior1YTDDuration-44000000JPY
Purchase of intangible assets inv cfCurrentYTDDuration-146000000JPY
Purchase of investment securities inv cfPrior1YTDDuration-1457000000JPY
Purchase of investment securities inv cfCurrentYTDDuration-19000000JPY
Proceeds from sales of investment securities inv cfPrior1YTDDuration134000000JPY
Proceeds from sales of investment securities inv cfCurrentYTDDuration226000000JPY
Proceeds from collection of guarantee deposits inv cfPrior1YTDDuration149000000JPY
Proceeds from collection of guarantee deposits inv cfCurrentYTDDuration3000000JPY
Proceeds from cancellation of insurance funds inv cfPrior1YTDDuration62000000JPY
Proceeds from cancellation of insurance funds inv cfCurrentYTDDuration79000000JPY
Other net inv cfPrior1YTDDuration-77000000JPY
Other net inv cfCurrentYTDDuration-61000000JPY
Net cash provided by used in investment activitiesPrior1YTDDuration-1851000000JPY
Net cash provided by used in investment activitiesCurrentYTDDuration-73000000JPY
Net increase decrease in short term loans payable fin cfPrior1YTDDuration500000000JPY
Net increase decrease in short term loans payable fin cfCurrentYTDDuration50000000JPY
Repayment of long term loans payable fin cfPrior1YTDDuration-2340000000JPY
Repayment of long term loans payable fin cfCurrentYTDDuration－JPY
Repayments of finance lease obligations fin cfPrior1YTDDuration-146000000JPY
Repayments of finance lease obligations fin cfCurrentYTDDuration-111000000JPY
Cash dividends paid fin cfPrior1YTDDuration-761000000JPY
Cash dividends paid fin cfCurrentYTDDuration-799000000JPY
Purchase of treasury stock fin cfPrior1YTDDuration-489000000JPY
Purchase of treasury stock fin cfCurrentYTDDuration-0JPY
Net cash provided by used in financing activitiesPrior1YTDDuration-3237000000JPY
Net cash provided by used in financing activitiesCurrentYTDDuration-860000000JPY
Effect of exchange rate change on cash and cash equivalentsPrior1YTDDuration0JPY
Effect of exchange rate change on cash and cash equivalentsCurrentYTDDuration-0JPY
Net increase decrease in cash and cash equivalentsPrior1YTDDuration-3428000000JPY
Net increase decrease in cash and cash equivalentsCurrentYTDDuration486000000JPY
Cash and cash equivalentsPrior2YearInstant12603000000JPY
Cash and cash equivalentsPrior1YearInstant10065000000JPY
Cash and cash equivalentsPrior1QuarterInstant9174000000JPY
Cash and cash equivalentsCurrentQuarterInstant10551000000JPY
Haulage expenses sgaPrior1YTDDuration144000000JPY
Haulage expenses sgaCurrentYTDDuration146000000JPY
Provision of allowance for doubtful accounts sgaPrior1YTDDuration0JPY
Provision of allowance for doubtful accounts sgaCurrentYTDDuration0JPY
Directors compensations sgaPrior1YTDDuration296000000JPY
Directors compensations sgaCurrentYTDDuration217000000JPY
Salaries and bonuses sgaPrior1YTDDuration1877000000JPY
Salaries and bonuses sgaCurrentYTDDuration1929000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2024-03-31pass rounding
balance sheet identityconsolidated 2024-09-30pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2024-03-31pass
statement vs summary · net assetsconsolidated 2024-09-30pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-09-30pass
statement vs summary · net income attributable to parentconsolidated 2024-04-01/2024-09-30pass
statement vs summary · operating cash flowconsolidated 2023-04-01/2023-09-30pass
statement vs summary · operating cash flowconsolidated 2024-04-01/2024-09-30pass
statement vs summary · revenueconsolidated 2023-04-01/2023-09-30pass
statement vs summary · revenueconsolidated 2024-04-01/2024-09-30pass
statement vs summary · total assetsconsolidated 2024-03-31pass
statement vs summary · total assetsconsolidated 2024-09-30pass